Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 11.55p 11.50p 11.60p 11.55p 11.55p 11.55p 950 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 68.3 -6.9 -1.3 - 74

Allergy Therapeutics Share Discussion Threads

Showing 3826 to 3849 of 3850 messages
Chat Pages: 154  153  152  151  150  149  148  147  146  145  144  143  Older
DateSubjectAuthorDiscuss
20/8/2019
17:42
Was that Skygem picking up a few more?
ewanwhose
01/8/2019
15:52
Brexit nerves impacting?
jimmyloser
17/7/2019
18:38
... But not quite enough to top up...
ewanwhose
17/7/2019
11:45
Bit of a sharp pull back....
audigger
11/7/2019
07:21
Video from FD Nick Wykeman re: this mornings trading update: hTTps://youtu.be/SvjBtruZ528
macc1
27/6/2019
14:24
Looks almost back to where we started yesterday. Disappointing end to the day
richsawko
27/6/2019
10:50
Didn't see that coming. Certainly reinforces the belief that the management team are on top of things. Proving to be a bit of a roller coaster ride this year! What would be impressive is if they can pull a rabbit out of the hat with a more favourable interpretation of the B301 Phase III trial for the birch product.
audigger
27/6/2019
08:03
Plenty of cash and can we dare hope for a bottom-line profit?
ewanwhose
27/6/2019
07:15
Breaking news Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Successful litigation settlement relating to PQ Grass Phase II Trial 27 June 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it has received a $7.6m settlement from Inflamax Research Inc. ("Inflamax") in relation to legal proceedings about the previously disclosed inconclusive Phase II Grass MATA MPL trial which took place in the USA in 2015-16. Inflamax has also agreed to pay a substantial part of the Group's legal costs. The clinical trial (G204) used mobile challenge chambers provided by Inflamax and preceded the successful Grass MATA MPL trial (G205) which the Group reported in June 2018. The Group commenced legal proceedings in the English High Court against Inflamax in March 2017 for breach of contract and misrepresentation concerning the G204 Study. Commenting on outcome, Manuel Llobet, CEO of Allergy Therapeutics, said: "ATL has always had full confidence in the Grass MATA MPL product and maintained that the inconclusive results of the G204 study were due to the inadequate procedures in the study. I am pleased that Inflamax have now compensated ATL for a significant proportion of the wasted study costs, as well as agreeing to pay the majority of the legal costs. Allergy Therapeutics aims to maintain the highest standards throughout its business and we are pleased that the matter has now been resolved."
jimmyloser
25/6/2019
11:25
About time Skygem topped up.
ewanwhose
14/6/2019
08:19
On Thursday Liu Xiaoming, China's ambassador to the UK, said that excluding Huawei from Britain's 5G network would "send a very bad signal". However, weak sterling gives Chinese investors an opportunity to buy more UK assets, says Monique Wong of Coutts. Chinese investment in the UK has largely been focused on the commercial property sector - "the iconic Cheesegrater was sold to Chinese investors a couple of years ago for just over a billion pounds", she says. "And don't forgot sterling is cheap, " she said, about 10% cheaper against the Chinese currency since the referendum. "It is an opportunity for Chinese investors and international investors more broadly," she said, adding that China's Fosun has expressed an interest in buying Thomas Cook's tour business. She also had a view on why was the market impact of the Hong Kong protests was limited - the Hang Seng stock index was down less than 0.5%. She said: "Usually the protests blow over... it doesn't really change our view on the region".
jimmyloser
11/6/2019
13:45
@jimmyloser Is Woodford buying in? If he was, the price would nosedive: maybe he's shorting it?
andrewbaker
11/6/2019
07:03
See above......Somebody likes the taste of peanuts. 15% of AGY for circa 11p a share !!!
jimmyloser
07/6/2019
10:49
Here we go again....are the Chinese investors looking for more than peanuts?
jimmyloser
06/6/2019
11:07
Chinese peanuts!
jimmyloser
05/6/2019
17:35
Well done Jimmy, very funny!!! :-)
nquaile875
05/6/2019
15:46
Is Woodford buying in?
jimmyloser
03/6/2019
19:19
A few positive words on peanuts over the next few days would not go amiss.
jimmyloser
03/6/2019
12:39
Good to see some buying today. Can't see any news anywhere.
ewanwhose
20/5/2019
07:22
Indeed thew mention of China appears a new line form the PR gurus they employ. Encouraging but early days yet and we know how perilous the journey can be. Would be good if it gave the share price another small jolt north
audigger
20/5/2019
07:06
A little encouraging news this morning from AGY and am I alone in noting the CHINA gets a first mention as a potential market?
jimmyloser
15/5/2019
13:41
Hmm....I wonder what is going on? Wonder what the detailed history is of ZQ investments internationally over time?
blather1
15/5/2019
13:24
There is a hierarchy of ZQ companies who own a hierarchy of Skygem companies - they are listed in the RNS
ewanwhose
15/5/2019
13:16
So a total of close to 30% of all AGY shares were snapped up in three (think it was three) momentous buys on one day and only part of those trades were accounted for by ZQ as mentioned in the RNS. Is Skygem and ZQ the same entity?
blather1
Chat Pages: 154  153  152  151  150  149  148  147  146  145  144  143  Older
Your Recent History
LSE
AGY
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190825 06:32:19